G-CLUSTER-GLOBAL
Broadmedia Corporation (location: Minato-ku, Tokyo. CEO: Taro Hashimoto) along with G-cluster Global Corporation (location: Minato-ku, Tokyo. President and Representative Director: Erik Piehl) will provide G-cluster technology1 for “DIVE IN,”2 a streaming service for Smartphones and Tablets operated by Square Enix Co., Ltd. (location: Shinjuku-ku, Tokyo. CEO: Yosuke Matsuda).
This streaming service for Smartphones and Tablets will be available from October 9th , 2014 on the SQUARE ENIX streaming service “DIVE IN” which is exclusive to Japan. By utilizing G-cluster technology, users can enjoy the many popular SQUARE ENIX games through their Smartphones and Tablets, without having to download or purchase game software.
- Link to DIVE IN: http://divein.jp.square-enix.com/
Broadmedia Corporation and G-cluster Global Corporation will continue to add new features for “DIVE IN”.
-1. What is G-cluster technology?
G‐cluster technology allows for streaming interactive content to various client devices without the need to download or install software. The video/audio output is streamed to a client device while all programs are executed at the server side. As the client device only needs to decode streamed data, the technology enables reliable and high quality services to be offered for all devices.
-2. What is DIVE IN?
DIVE IN is a streaming service operated by Square Enix Co., Ltd. that allows users to play from oldest to latest SQUARE ENIX games through Wi-Fi.
Along with the launching of the service on October 9th , “FINAL FANTASY VII International”, “FINAL FANTASY XIII”, and “Season of Mystery: The Cherry Blossom Murders” will be available. And from November, “FINAL FANTASY VIII”, “THE LAST REMNANTTM ”, “Murdered: Soul Suspect”, “FINAL FANTASY XIII-2”, and
“LIGHTNING RETURNSTM : FINAL FANTASY XIII” will be released. 30-minute free trials will be offered for all released titles.
- About SQUARE ENIX CO., LTD.
Square Enix Co., Ltd. develops, publishes, distributes and licenses SQUARE ENIX®, EIDOS® and TAITO® branded entertainment content around the world. The Square Enix Group operates a global network of leading development studios and boasts a valuable portfolio of intellectual property, including: FINAL FANTASY®, which has sold over 110 million units worldwide, and DRAGON QUEST® which has sold over 64 million units worldwide; TOMB RAIDER®, which has sold over 42 million units worldwide; and the legendary SPACE INVADERS®. Square Enix is a Japan-based, wholly-owned subsidiary of Square Enix Holdings Co., Ltd
More information on Square Enix Co., Ltd. can be found at http://www.jp.square-enix.com/
*Square Enix and Square Enix Logo games, Dragon Quest, Final Fantasy, Tomb Raider, Space Invaders, DIVE IN, and any other company or product names are registered trademarks of the Square Enix group inside and outside Japan.
Press Release URL： http://www.gcluster.com/eng/pdf/20140909_001_E.pdf
©SQUARE ENIX CO., LTD. All rights reserved.
Contact:
G-cluster
Broadmedia
Corporation, Home Entertainment Group
Toshihiko Tamura / Junko
Matsuda
+81-3-6439-3714
or
G-cluster Global
Corporation, Global Management Dev.
Motohiro Shindo
+81-3-6439-3732
or
Press
Broadmedia
Corporation, PR Group
E-mail: cmktg@broadmedia.co.jp
TEL:
+81-3-6439-3983
FAX: +81-3-3478-7014
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release
- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc
Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology6.6.2025 16:00:00 CEST | Press release
IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine.With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty.This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 14:00:00 CEST | Press release
Pivotal Study Advances to Establish Histotripsy as a Non-Thermal, Surgery-Free Alternative to Destroy and Liquefy Kidney Tumors HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison
Norwegian Tech Firm Builds Military Command Center in 24 Hours6.6.2025 13:45:00 CEST | Press release
Norwegian technology provider Cyviz has successfully developed a fully mobile and ballistic-proof command center - designed, configured, and made operational in just 24 hours. The solution was showcased during a military exercise led by the Dutch Ministry of Defence and has already sparked interest from NATO members and civil protection agencies across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606640770/en/ Cyviz demonstrates rapid deployment capability with a mobile, container-based control room for defense and crisis response Cyviz and its partners constructed the command room inside a 14-ton container designed for transport on standard military vehicles and resistant to machine gun fire. The unit was deployed at a military base in the Netherlands, where Cyviz was tasked with delivering a fully functional command-and-control environment, under strict time constraints and in a high-stakes simulation. "You do
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum